for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cadila Healthcare Ltd

CADI.NS

Latest Trade

234.70INR

Change

0.25(+0.11%)

Volume

688,266

Today's Range

232.20

 - 

237.60

52 Week Range

206.50

 - 

387.40

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
234.45
Open
235.00
Volume
688,266
3M AVG Volume
29.06
Today's High
237.60
Today's Low
232.20
52 Week High
387.40
52 Week Low
206.50
Shares Out (MIL)
1,023.74
Market Cap (MIL)
240,016.50
Forward P/E
15.74
Dividend (Yield %)
1.49

Next Event

Q2 2020 Cadila Healthcare Ltd Earnings Release

Latest Developments

More

Cadila Healthcare Says API Manufacturing Facility At Dabhasa Completes U.S. FDA Inspection

Cadila Healthcare Says Zydus Gets Positive Results From Clinical Trial Of Saroglitazar Magnesium In NAFLD And NASH

Cadila Healthcare Unit Gets USFDA Nod For Clobetasol Propionate Lotion

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cadila Healthcare Ltd

Cadila Healthcare Limited is an India-based pharmaceutical company. The Company's subsidiaries include Zydus Wellness Limited, Windlas Healthcare Pvt Ltd, Liva Pharmaceuticals Limited, Biochem Pharmaceutical Industries Limited, Zydus Technologies Limited, German Remedies Limited, Dialforhealth India Limited, Dialforhealth Unity Limited and Dialforhealth Greencross Limited, among others.

Industry

Biotechnology & Drugs

Contact Info

Zydue Tower, Satellite Cross Road

+91.79.26868100

http://zyduscadila.com/

Executive Leadership

Pankaj Ramanbhai Patel

Executive Chairman of the Board

Nitin D. Parekh

Chief Financial Officer

Ganesh N. Nayak

Chief Operating Officer, Whole Time Director

Sharvil P. Patel

Managing Director, Director

Dhaval N. Soni

Company Secretary

Key Stats

2.17 mean rating - 36 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2017

97.5K

2018

119.0K

2019

131.7K

2020(E)

141.3K
EPS (INR)

2017

14.820

2018

17.350

2019

18.060

2020(E)

14.852
Price To Earnings (TTM)
14.18
Price To Sales (TTM)
1.74
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
10.23
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up